[O9] Oral Session 9　Genitourinary Cancer
【E】

[O9-5] Enzalutamide versus abiraterone as a first-line endocrine therapy for CRPC: ENABLE study for PCa

^○Kouji Izumi¹, Takashi Shima², Koji Mita³, Yuki Kato^1,16, Manabu Kamiyama⁴, Shogo Inoue⁵, Nobumichi Tanaka⁶, Seiji Hoshi⁷, Takehiko Okamura⁸, Yuko Yoshio⁹, Hideki Enokida¹⁰, Ippei Chikazawa¹¹, Noriyasu Kawai¹², Kohei Hashimoto¹³, Takashi Fukagai¹⁴, Kazuyoshi Shigehara^1,17, Shizuko Takahara¹⁵, Yoshifumi Kadono¹, Atsushi Mizokami¹ (1.Department of Urology and Integrative Cancer Therapy, Kanazawa University, 2.Department of Urology, Toyama Prefectural Central Hospital, 3.Department of Urology, Hiroshima City Asa Citizens Hospital, 4.Department of Urology, University of Yamanashi, 5.Department of Urology, Institute of Biomedical and Health Science, Hiroshima University, 6.Department of Urology, Nara Medical University, 7.Department of Urology, Fukushima Medical University, 8.Department of Urology, Anjo Kosei Hospital, 9.Nephro-Urologic Surgery and Andrology, Division of Reparative and Regenerative Medicine, Institute of Medical Life Science, Mie University Graduate School of Medicine, 10.Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, 11.Department of Urology, Kanazawa Medical University, 12.Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, 13.Department of Urology, School of Medicine, Sapporo Medical University, 14.Department of Urology, Showa University Koto Toyosu Hospital, 15.Innovative Clinical Research Center, Kanazawa University, 16.Department of Urology, Fukui-ken Saiseikai Hospital, 17.Department of Urology, Ishikawa Prefectural Central Hospital)